Evidence map›Paper›PMID 41181986›Full record

ArticleEndocrinology, diabetes & metabolism case reports2025

The relevance of patient-reported outcome measures in hypopituitarism: HIV therapy adherence and suicidal ideations resolved by GH replacement.

Linus Hesse, Loreen Richter, Lukas Maurer, Joachim Spranger, Knut Mai, Christian J Strasburger, Linus Haberbosch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Linus HesseCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.ORCID https://orcid.org/0009-0002-9578-011X
Loreen RichterCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.
Lukas MaurerCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.
Joachim SprangerCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.
Knut MaiCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.
Christian J StrasburgerCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.
Linus HaberboschCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism; European Reference Network On Rare Endocrine Diseases (ENDO-ERN),Berlin, Germany.ORCID https://orcid.org/0000-0002-4464-0427

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Summary: Extensive research has examined the effects of growth hormone (GH) replacement therapy for patients with hypopituitarism and GH deficiency. Positive outcomes, encompassing both conventional clinical markers and improvements in quality of life (QoL), have led to its incorporation in current clinical practice guidelines. Herein, we present how routine use of the patient-reported outcome measures information system (PROMIS) as an intuitive tool portraying patient-reported outcome measures (PROMs) can help guide and follow-up therapeutic decisions and bridge the gap between clinical parameters and patient experiences. This approach is illustrated by a patient with panhypopituitarism and HIV with low antiretroviral medication adherence. Following the initiation of GH replacement therapy, PROMIS assessments documented QoL improvements that enabled full resumption of antiretroviral medication, accompanied by resolution of previously experienced adverse effects. Learning points: GH replacement can be an important component of hormone replacement therapy in individuals with hypopituitarism and suicidal ideations. Incorporating PROMs into endocrinological care can help guide therapy decisions in patients with hypopituitarism. Clinical signs attributed to side effects of antiretroviral therapy may overlap with those of GH deficiency, and GH replacement therapy can potentially increase medication adherence.

Indexed as

growth hormoneHIVhypopituitarismPROMsquality of life

Identifiers

PMID41181986
PMCPMC12591627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.